Related Experiment Video

Updated: Mar 31, 2026

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
07:52

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

Published on: November 2, 2020

7.2K

Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma

Norihiko Tokuzen1, Koh-ichi Nakashiro1, Hiroshi Tanaka1

  • 1Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan.

Oncotarget
|October 27, 2015
PubMed

Insights

Targeting cell division cycle associated 5 (CDCA5) shows promise for oral squamous cell carcinoma (OSCC) therapy. Inhibiting CDCA5 significantly reduced OSCC cell growth and invasion, suggesting it as a key therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Molecularly targeted therapies have advanced cancer treatment, but progress for oral squamous cell carcinoma (OSCC) has been slower.
  • Identifying novel molecular targets is crucial for developing effective OSCC therapies.

Purpose of the Study:

  • To investigate the expression and functional role of cell division cycle associated 5 (CDCA5) in oral squamous cell carcinoma (OSCC).
  • To evaluate CDCA5 as a potential therapeutic target for OSCC.

Main Methods:

  • Microarray analysis to identify overexpressed genes in OSCC.
  • Quantitative RT-PCR and Western blotting to confirm CDCA5 expression in OSCC cell lines.
  • Small interfering RNA (siRNA) to knockdown CDCA5 expression.
  • In vitro and in vivo assays to assess the effect of CDCA5 knockdown on cell growth and invasion.
  • Immunohistochemical analysis of CDCA5 expression in 80 OSCC patient samples.

Main Results:

  • CDCA5 was found to be overexpressed in human OSCC cell lines.
  • Knockdown of CDCA5 significantly inhibited OSCC cell growth both in vitro and in vivo.
  • Higher CDCA5 expression levels in patient samples were significantly associated with poorer overall survival.

Conclusions:

  • CDCA5 is a critical gene that promotes the progression of oral squamous cell carcinoma (OSCC).
  • Targeting CDCA5 represents a promising therapeutic strategy for the treatment of OSCC.
Keywords:
cell cyclecell division cycle associated 5 (CDCA5)molecular targeted therapyoral squamous cell carcinoma (OSCC)prognosis

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K